Halozyme Therapeutics, Inc.
HALO
$107.39
-$0.92-0.85%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 27.68% | -16.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 27.68% | -16.61% | |||
| Cost of Revenue | 1.94% | -5.30% | |||
| Gross Profit | 37.61% | -20.28% | |||
| SG&A Expenses | -1.53% | -8.60% | |||
| Depreciation & Amortization | 0.00% | 26.25% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.60% | -2.62% | |||
| Operating Income | 55.90% | -27.47% | |||
| Income Before Tax | 57.99% | 278.81% | |||
| Income Tax Expenses | 81.61% | -25.68% | |||
| Earnings from Continuing Operations | 53.23% | 205.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 53.23% | 205.97% | |||
| EBIT | 55.90% | -27.47% | |||
| EBITDA | 47.98% | -22.73% | |||
| EPS Basic | 54.36% | 205.55% | |||
| Normalized Basic EPS | 59.19% | -28.62% | |||
| EPS Diluted | 55.74% | 201.39% | |||
| Normalized Diluted EPS | 60.18% | -31.37% | |||
| Average Basic Shares Outstanding | -0.74% | 0.40% | |||
| Average Diluted Shares Outstanding | -1.35% | 4.42% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||